Platelet Aggregation Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Platelets are one of the formed elements of blood, along with RBCs and WBCs and play a very important role in physiological hemostasis and thrombus formation. These inhibit the cascade steps in the primary hemostasis phase to pervert platelet plug formation inside the blood vessels, thus preventing the blocking of blood vessels. However, it is also a key pathophysiological factor in developing arterial ischaemic events, including coronary artery disease, cerebrovascular accidents, and peripheral arterial disease. Platelet Aggregation Inhibitors therapy finds a role in preventing recurrent events in individuals affected by one of these conditions. The very initial therapy was with Aspirin and Clopidogrel, which were the very initial drugs used to prevent platelet aggregation However, this landscape has changed dramatically with the advent of newer and more potent agents like Prasugrel and Ticagrelor. New classes of drugs like glycoprotein IIb/IIIa receptor antagonists have changed the market dynamics, which are more potent and reliable. According to the British Heart Foundation, there are about 620 million people living with heart and circulatory diseases globally. According to the U.S. Department of Health & Human Services, about 1 in 20 adults above the age of 20 are suffering from coronary artery disease  (CAD) which accounts for 5% of the population of the USA. Several factors that are responsible for rising heart diseases are Changing lifestyles, High Blood Pressure, High Cholesterol levels, Unhealthy diet and/or overeating, Obesity, alcohol consumption, smoking, and others. A number of these antagonists are in the market while many are ongoing clinical trials. 34 companies have various products in their pipelines with 28 products in various stages of clinical trials. 6 products are in Phase 4, 7 products are in Phase 3, 4 products are in Phase 2 while 4 products are in Phase 1 of the clinical trials.

Key Developments:

• In May 2022, Tyvaso (Treprostinil) received FDA approval for the treatment of patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension associated with Interstitial Lung Disease.
• In November 2022, a Phase 1 clinical trial was initiated for Vicagrel in China to study the pharmacokinetics and pharmacodynamics of the drug.

Approved drugs

• Clotinab (Abciximab) - Isu Abxis
• Tyvaso (Treprostinil) – United Therapeutic Corporation
• Disgren (Triflusal) – Uriach Pharma
• Indobufan - Pfizer
• Opalmon (Limaprost) – Ono Pharmaceutical Co., Ltd.
• Renexin CR (Cilastozol/Gingko Biloba SR) - SK Biopharmaceuticals

Drugs in Pipeline

• INS1009 (Treprostinil palmitil inhalation)
• Vicagrel
• Q-Force (Quercetin)
• PB2452 (Bentracimab)
• Beraprost 314d (Esyuberaprost)
• Sapodifil SR (Sarpogrelate SR)
• Teluron (Terguride)
• AZD6482
• LIQ861 (Treprostinil inhaled dry powder)
• Bezalip SR (Bezafibrate)
• MND-2119 (Icosapent)
• L-606 (Treprostinil liposomal)
• AZD3366
• D-003
• Jotrol (trans resveratrol oral)
• MSCO-157 (Captisol enabled clopidogrel

Clinical Activity and Developments of Platelet Aggregation Inhibitors

Companies have their products in the pipeline in various phases of clinical trials with approximately 28 products for above 118 diseases.

• In February 2023, Science Valley Research Institute completed a Phase 4 trial of Rivaroxaban and Aspirin for intermittent claudication in Pulmonary Arterial Disease patients.
• In March 2023, Mayo Clinic completed a Phase 4 trial to evaluate the effectiveness of Clopidogrel monotherapy in patients with high bleeding risk.
• In December 2022, completed a Phase 4 trial evaluating the safety and efficacy of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.